- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02916017
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Kagoshima, Japan, 890-8520
- Kagoshima Uni Med and Dental /ID# 164150
-
Kakogawa, Japan, 489-0065
- Kakogawa Central City Hospital /ID# 167706
-
Miyakonojo, Japan, 885-0051
- Miyata Ophthalmic Hospital /ID# 167707
-
Nishinomiya-shi, Japan, 663-8501
- Duplicate_The Hospital of Hyogo College /ID# 166913
-
Omihachiman, Japan, 523-0082
- Omihachiman Community Med Ctr /ID# 164978
-
Osaka, Japan, 572-0854
- Osaka Hospital /ID# 164151
-
Osaka-shi, Japan
- Yodogawa Christian Hospital /ID# 161741
-
Seto, Japan, 489-8642
- Tosei General Hospital /ID# 167708
-
Tokorozawa, Japan, 359-0042
- Natl Defense Med College Hosp /ID# 162946
-
Tokyo, Japan, 108-6303
- Abbott Japan /ID# 147893
-
Tokyo, Japan, 162-8543
- Tokyo Shinjuku Medical Center /ID# 166934
-
Tottori, Japan, 680-8501
- Tottori Municipal Hospital /ID# 159431
-
-
Chiba
-
Urayasu-shi, Chiba, Japan, 279-0021
- Juntendo University Urayasu Hospital /ID# 168358
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 790-0826
- Matsuyama Red Cross Hospital /ID# 164149
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 812-8582
- Kyushu University Hospital /ID# 163042
-
Fukuoka-shi, Fukuoka, Japan, 814-0180
- Fukuoka University Hospital /ID# 163043
-
Kurume-shi, Fukuoka, Japan, 830-0011
- Kurume University Hospital /ID# 162945
-
-
Gunma
-
Maebashi-shi, Gunma, Japan, 371-8511
- Gunma University Hospital /ID# 166916
-
-
Hiroshima
-
Hiroshima-shi, Hiroshima, Japan, 734-8551
- Hiroshima University Hospital /ID# 166915
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital /ID# 163041
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0017
- Kobe University Hospital /ID# 165250
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan, 920-8641
- Duplicate_Kanazawa University Hospital /ID# 166914
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 240-8555
- Yokohama Municipal Citizen's Hospital /ID# 161742
-
-
Kochi
-
Nankoku-shi, Kochi, Japan, 783-8505
- Kochi Medical School Hospital /ID# 164144
-
-
Nagano
-
Matsumoto-shi, Nagano, Japan, 390-8621
- Shinshu University Hospital /ID# 164153
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 951-8520
- Niigata University Medical & Dental Hospital /ID# 169563
-
-
Osaka
-
Suita-shi, Osaka, Japan, 565-0871
- Osaka University Hospital /ID# 164147
-
-
Saitama
-
Iruma-gun, Saitama, Japan, 350-0451
- Saitama Medical University Hospital /ID# 162944
-
-
Tochigi
-
Shimotsuga-gun, Tochigi, Japan, 321-0293
- Dokkyo Medical University Hospital /ID# 164154
-
-
Tokushima
-
Tokushima-shi, Tokushima, Japan, 770-8503
- Tokushima University Hospital /ID# 164145
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8431
- Juntendo University Hospital /ID# 169564
-
Bunkyo-ku, Tokyo, Japan, 113-8519
- Tokyo Medical And Dental University, Medical Hospital /ID# 165251
-
Bunkyo-ku, Tokyo, Japan, 113-8603
- Nippon Medical School Hospital /ID# 166938
-
Bunkyo-ku, Tokyo, Japan, 113-8655
- The University of Tokyo Hospital /ID# 162943
-
Minato-ku, Tokyo, Japan, 105-8471
- The Jikei University Hospital /ID# 164152
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital /ID# 164146
-
Shinjuku-ku, Tokyo, Japan, 162-8655
- Center Hospital of the National Center for Global Health and Medicine /ID# 164148
-
Shinjuku-ku, Tokyo, Japan, 162-8666
- Tokyo Women's Medical University Hospital /ID# 165248
-
-
Yamaguchi
-
Ube-shi, Yamaguchi, Japan, 755-8505
- Yamaguchi University Hospital /ID# 165249
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
Exclusion Criteria:
- Participants previously treated with adalimumab
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
---|
Participants receiving adalimumab
Participants receiving adalimumab for the treatment of Non-infectious Intermediate-, Posterior-, or Pan-uveitis
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of adverse drug reactions (ADR)
Tidsram: Up to Week 52
|
ADR is the causal relationship between adalimumab and adverse events.
|
Up to Week 52
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Visual Functioning Questionnaire (VFQ)-25 score
Tidsram: From Week 0 (baseline) to Week 52
|
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning.
The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question.
The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
|
From Week 0 (baseline) to Week 52
|
Change in Visual acuity in each eye
Tidsram: From Week 0 (baseline) to Week 52
|
Visual acuity change is assessed.
|
From Week 0 (baseline) to Week 52
|
Change in Anterior Chamber (AC) cell grade (standardization of uveitis nomenclature (SUN) criteria) in each eye
Tidsram: From Week 0 (baseline) to Week 52
|
Slit lamp examinations will be conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam will be used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = < 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = > 50 cells. |
From Week 0 (baseline) to Week 52
|
Percentage of Overall improvement
Tidsram: Up to Week 52
|
This is assessed by physicians.
|
Up to Week 52
|
Change in retinal lesions in each eye
Tidsram: From Week 0 (baseline) to Week 52
|
The change in retinal lesion are assessed.
|
From Week 0 (baseline) to Week 52
|
Change in central retinal thickness in each eye
Tidsram: From Week 0 (baseline) to Week 52
|
This is assessed by Optical Coherence Tomography (OCT)
|
From Week 0 (baseline) to Week 52
|
Change in Vitreous Haze grade in each eye
Tidsram: From Week 0 (baseline) to Week 52
|
Vitreous haze will be measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI)/ SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured. |
From Week 0 (baseline) to Week 52
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P15-665
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .